ClinicalTrials.gg
CompletedNCT00836706Updated Aug 20, 2024Results posted

Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

A Phase 1 interventional study of clarithromycin and BIAXIN® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will compare the relative bioavailability (rate and extent of absorption) of 500 mg Clarithromycin Tablets with that of 500 mg BIAXIN® Tablets following a single oral dose (1 x 500 mg tablet) in healthy adult subjects under non-fasting conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects selected for this study will be healthy men or women 18 years of age or older at the time of dosing. The subject's (BMI) should be less than or equal to 30.

Each subject will complete the screening process within 28 days prior to period I dosing. Consent documents for both the screening evaluation and antibody determination will be reviewed, discussed and signed by each potential participant before full implementation of screening procedures.

Screening will include general observations, physical examination, demographics, medical and medication history, an , sitting blood pressure and heart rate, respiratory rate and temperature. The physical examination will include, but may not be limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems.

The screening clinical laboratory procedures will include:

HEMATOLOGY: hematocrit, , WBC count with differential, RBC count, count CLINICAL CHEMISTRY: serum creatinine, BUN, glucose, (GOT), ALT(GPT), albumin, total , total protein, and alkaline phosphatase HIV antibody, surface antigen, antibody screens URINALYSIS: by dipstick; full microscopic examination if dipstick positive URINE DRUG SCREEN: ethyl alcohol, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolites, opiates and phencyclidine SERUM PREGNANCY SCREEN (female subjects only) FOLLICLE STIMULATING HORMONE (FSH; female subjects only): verify status

If female and :

is postmenopausal for at least 1 year; or is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).

Exclusion criteria

Exclusion Criteria:

Subjects with a recent history of drug or alcohol addiction or abuse. Subjects with the presence of a disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigators).

Subjects whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.

Subjects demonstration a positive surface antigen screen, antibody screen or a reactive antibody screen.

Subjects demonstrating a positive drug abuse screen when screened for this study.

Female subjects who are currently breast feeding. Female subjects who are demonstrating a positive pregnancy screen. Subjects with a history of allergic response(s) to Clarithromycin or related drugs.

Subjects with a history of clinically significant allergies including drug allergies.

Subjects with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).

Subjects who currently use or reports using tobacco or nicotine-containing products within 90 days prior to Period I dosing.

Subjects who have taken any drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to Period I dosing.

Subjects who report donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects will by advised not to donate blood for four weeks after completing the study.

Subjects who have donated plasma (e.g. plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study.

Subjects who report receiving any drug within 30 days prior to Period I dosing.

Subjects who report taking any prescription medication in the 14 days prior to Period I dosing, with the exception of topical products without systemic absorption.

Subjects who have been on an abnormal diet during the 28 days prior to Period I dosing.

Subjects who report an intolerance of direct venipuncture.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Clarithromycin (test)

    Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period

    Drug: clarithromycin

  • Active comparator
    Biaxin®

    Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period

    Drug: BIAXIN®

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax - Maximum Observed Concentration

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over 48 hour period

  2. AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

    Bioequivalence based on AUC0-inf

    Time frame: Blood samples collected over 48 hour period

  3. AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 48 hour period

07

Results

Posted Jul 21, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneClarithromycin (Test) FirstBiaxin® (Reference) First
Started1112
Completed1112
Not completed00
Washout: 7 Days
Participant flow — Washout: 7 Days
MilestoneClarithromycin (Test) FirstBiaxin® (Reference) First
Started1112
Completed1111
Not completed01
Withdrew: Withdrawal by subject01
Second Intervention
Participant flow — Second Intervention
MilestoneClarithromycin (Test) FirstBiaxin® (Reference) First
Started1111
Completed1111
Not completed00

Outcome measures

PrimaryCmax - Maximum Observed Concentration

Bioequivalence based on Cmax

Time frame:
Blood samples collected over 48 hour period
Reported as:
Mean · ng/mL
Cmax - Maximum Observed Concentration
ng/mLClarithromycinBiaxin®
Cmax - Maximum Observed Concentration2440.545 ± 764.7732414.955 ± 859.636
Statistical analysis
  • Clarithromycin vs Biaxin® · Test/ref ratio of ls means x 100: 101 · 90% CI 85.2 to 120Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUC0-inf

Time frame:
Blood samples collected over 48 hour period
Reported as:
Mean · ng*h/mL
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
ng*h/mLClarithromycinBiaxin®
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)13509.616 ± 4764.22813278.682 ± 4643.690
Statistical analysis
  • Clarithromycin vs Biaxin® · Test/ref ratio of ls means x 100: 101 · 90% CI 88.7 to 114Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 48 hour period
Reported as:
Mean · ng*h/mL
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration
ng*h/mLClarithromycinBiaxin®
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration13424.597 ± 4778.31513192.468 ± 4606.320
Statistical analysis
  • Clarithromycin vs Biaxin® · Test/ref ratio of ls means x 100: 101 · 90% CI 88.4 to 114Bioequivalence is established when 90% Confidence Interval falls within 80-125.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Clarithromycin (Test) FirstBiaxin® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years111223
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Clarithromycin (Test) FirstBiaxin® (Reference) FirstTotal
Female101
Male101222
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Clarithromycin (Test) FirstBiaxin® (Reference) FirstTotal
Caucasian111021
Black011
Asian011
Region of Enrollment
Region of Enrollment(participants)Clarithromycin (Test) FirstBiaxin® (Reference) FirstTotal
United States111223
08

Study locations

1 site
  • PRACS Institute, Ltd.
    East Grand Forks, Minnesota 56721, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002, a primary completion of Jul 2002 and a completion of Jul 2002. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 7 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2009
First posted
Feb 4, 2009
Start
Jul 2002
Primary completionActual
Jul 2002
CompletionActual
Jul 2002
Results first posted
Jul 21, 2009
Last update
Aug 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00836706
First posted
Feb 4, 2009
Start date
Jul 2002
Primary completion
Jul 2002
Completion
Jul 2002
Results posted
Jul 21, 2009
Last update
Aug 20, 2024

Study contacts

James D Carlson, Pharm. D.
principal investigator · PRACS

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clarithromycin

Start the discussion